ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. On 31 December 2023, the US$2.9b market-cap company posted a loss of US$61m for its most recent financial year. Many investors are wondering about the rate at which ACADIA Pharmaceuticals will turn a profit, with the big question being "when will the company breakeven?" Below we will provide a high-level summary of the industry analysts' expectations for the company.
阿卡迪亚制药公司(纳斯达克股票代码:ACAD)的业务可能即将取得重大成就,因此我们想对该公司有所了解。生物制药公司ACADIA Pharmaceuticals Inc. 专注于创新药物的开发和商业化,以解决美国中枢神经系统(CNS)疾病和罕见疾病中未得到满足的医疗需求。2023年12月31日,这家市值29亿美元的公司公布其最近一个财政年度的亏损为6100万美元。许多投资者想知道阿卡迪亚制药的盈利速度,最大的问题是 “公司何时会实现盈亏平衡?”下面,我们将概述行业分析师对公司的期望。
According to the 21 industry analysts covering ACADIA Pharmaceuticals, the consensus is that breakeven is near. They expect the company to post a final loss in 2023, before turning a profit of US$112m in 2024. Therefore, the company is expected to breakeven roughly 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 42%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
根据报道阿卡迪亚制药的21位行业分析师的说法,人们的共识是盈亏平衡已临近。他们预计,该公司将在2023年公布最终亏损,然后在2024年实现1.12亿美元的盈利。因此,预计该公司将在大约12个月后或更短的时间内实现盈亏平衡。为了实现预期在不到12个月的时间内实现盈亏平衡的共识估计,公司必须以什么速度增长?使用最合适的线,我们计算出平均年增长率为42%,这表明分析师充满信心。如果事实证明这个利率过于激进,该公司的盈利时间可能比分析师预测的要晚得多。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240328/0-8e2fba1f970c13a72bb29e25914f5699-0-ec0dc8e3a37b0561390973663e5a7230.png/big)
We're not going to go through company-specific developments for ACADIA Pharmaceuticals given that this is a high-level summary, though, bear in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
鉴于这是一份高层次的摘要,我们不打算详细介绍阿卡迪亚制药公司的具体发展情况,但请记住,生物技术公司的现金流周期通常不规律,具体取决于产品开发阶段。这意味着高增长率并不罕见,尤其是在公司目前处于投资期的情况下。
One thing we'd like to point out is that ACADIA Pharmaceuticals has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
我们想指出的一件事是,阿卡迪亚制药的资产负债表上没有债务,这对于一个消耗现金的生物技术公司来说是很不寻常的,因为相对于股权而言,债务通常很高。该公司目前完全靠股东资金运营,没有债务义务,这减少了对还款的担忧,使其成为一项风险较小的投资。
Next Steps:
后续步骤:
There are too many aspects of ACADIA Pharmaceuticals to cover in one brief article, but the key fundamentals for the company can all be found in one place – ACADIA Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of essential factors you should further examine:
阿卡迪亚制药公司有很多方面无法在一篇简短的文章中介绍,但该公司的关键基本面都可以在一个地方找到——ACADIA Pharmaceuticals在Simply Wall St的公司页面。我们还整理了一份你应该进一步研究的基本因素清单:
- Valuation: What is ACADIA Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether ACADIA Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on ACADIA Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:阿卡迪亚制药今天的价值是多少?价格中是否已经考虑了未来的增长潜力?我们的免费研究报告中的内在价值信息图有助于可视化阿卡迪亚制药公司目前是否被市场定价错误。
- 管理团队:一支经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是阿卡迪亚制药董事会成员以及首席执行官的背景。
- 其他表现优异的股票:还有其他股票可以提供更好的前景并有良好的往绩记录吗?在这里浏览我们免费列出的这些优质股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。